Arvinas Revenue and Competitors

New Haven, CT USA

Location

$111.6M

Total Funding

Biotech

Industry

Estimated Revenue & Valuation

  • Arvinas's estimated annual revenue is currently $22.6M per year.(i)
  • Arvinas received $55.0M in venture funding in April 2018.
  • Arvinas's estimated revenue per employee is $53,028
  • Arvinas's total funding is $111.6M.
  • Arvinas's current valuation is $3.6B. (January 2022)

Employee Data

  • Arvinas has 426 Employees.(i)
  • Arvinas grew their employee count by 15% last year.
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$0.9M60%N/AN/A
#2
$3.7M24-8%N/AN/A
#3
$9.8M617%N/AN/A
#4
$1.4M9350%N/AN/A
#5
$21.5M139-11%N/AN/A
#6
$5.7M3728%N/AN/A
#7
$1.7M1157%N/AN/A
#8
$2.5M16129%N/AN/A
#9
$0.3M4-43%N/AN/A
#10
$4M2618%N/AN/A
Add Company

Arvinas is a pharmaceutical company focused on developing new small molecules - known as PROTACs (PROteolysis TArgeting Chimeras) - aimed at degrading disease-causing cellular proteins via proteolysis. Based on innovative research conducted at Yale University by Dr. Craig Crews, Founder and Chief Scientific Advisor, the company is translating natural protein degradation approaches into novel drugs for the treatment of cancer and other diseases. The proprietary PROTAC-based drug paradigm induces protein degradation, rather than protein inhibition, using the ubiquitin proteasome system and offers the advantage of potentially targeting undruggable as well as druggable elements of the proteome. This greatly expands the ability to create drugs for many new, previously unapproachable targets. For more information, visit www.arvinas.com.

keywords:Biotechnology,Healthcare,Marketing,Pharmaceuticals

$111.6M

Total Funding

426

Number of Employees

$22.6M

Revenue (est)

15%

Employee Growth %

$3.6B

Valuation

N/A

Accelerator

Arvinas News

2022-04-19 - Arvinas, Inc. (NASDAQ:ARVN) Expected to Post Quarterly Sales of $29.11 Million

On average, analysts expect that Arvinas will report full year sales of $131.08 million for the current financial year, with estimates ranging...

2022-04-17 - Zacks: Analysts Expect Arvinas, Inc. (NASDAQ:ARVN) Will ...

Zacks: Analysts Expect Arvinas, Inc. (NASDAQ:ARVN) Will Announce Quarterly Sales of $29.11 Million. Posted by admin on Apr 22nd, 2022.

2022-04-17 - Zacks: Brokerages Expect Arvinas, Inc. (NASDAQ:ARVN) Will ...

Arvinas reported earnings of ($0.84) per share during the same quarter last year, which would indicate a negative year-over-year growth rate of...

2019-09-08 - Arvinas To Present at the Wedbush PacGrow Healthcare ...

NEW HAVEN, Conn. , Aug. 07, 2019 (GLOBE NEWSWIRE) — Arvinas Inc. (Nasdaq: ARVN), a biotechnology company creating a new class of ...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$75M500N/AN/A
#2
$114.1M507N/AN/A
#3
$307.6M521-46%$443.7M
#4
$149.9M545-6%N/A
#5
$195.1M5786%N/A

Arvinas Funding

DateAmountRoundLead InvestorsReference
2013-09-27$15.0MAArticle
2015-10-22$41.6MBRA Capital ManagementArticle
2018-04-05$55.0MCNextech InvestArticle